|
|
|
|
|
|
|
09.05.25 - 22:09
|
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter′s Option to Purchase Additional Shares (GlobeNewswire EN)
|
|
|
CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, pursuant to the full exercise of the option granted by Exagen to the underwriter in connection with its previously announced public offering of 3,350,000 shares of common stock, which closed on May 9, 2025....
|
|
|
|
|
08.05.25 - 14:33
|
Exagen Inc. Prices Public Offering of Common Stock (GlobeNewswire EN)
|
|
|
CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share. All of the shares in the offering will be sold by Exagen, with gross proceeds to Exagen expected to be $17,587,500 before deducting underwriting discounts and commissions and offering expenses. Exagen has granted the underwriters a 30-day option to purchase up to an additional 502,500 shares on the same terms and conditions. The offering is expected to close on May 9, 2025, subject to the satisfaction of customary closing conditions....
|
|
|
|
|
|
|
|
|
21.04.25 - 22:09
|
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025 (GlobeNewswire EN)
|
|
|
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on Monday, May 5, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT)....
|
|
|
|
|
|
|
|
|
25.02.25 - 22:06
|
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025 (GlobeNewswire EN)
|
|
|
CARLSBAD, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2024, before the market opens on Tuesday, March 11, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 AM ET (5:30 AM PT)....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
